{"created":"2023-05-15T14:51:49.017762+00:00","id":70834,"links":{},"metadata":{"_buckets":{"deposit":"5adf0de6-2bb1-4526-83bb-8aef80a89163"},"_deposit":{"created_by":1,"id":"70834","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"70834"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00070834","sets":["10:28"]},"author_link":["695975","695968","695974","695971","695969","695970","695976","695973","695967","695972"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2012-07-21","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Purpose: To evaluate the value of hyperfractionated radiotherapy with concurrent use of low dose docetaxel in locally advanced head and neck cancer.\nMethods: Patients eligible for this study had confirmed diagnosis of squamous cell carcinoma stages II (>10 m3), III, IVA and IVB of the head and neck. Radiotherapy was delivered twice a day at 1.2 Gy/fraction to a total dose of 72.0 Gy. Docetaxel (10 mg/m2) was administered weekly during radiotherapy.\nResults: From March 2003 to October 2008, 70 patients were treated. Primary sites included the oropharynx (n=25), hypopharynx (n=24), larynx (n=18), and other sites (n= 3). Stages II (n=11), III (n=16), IVA (n=33) were included. Major grade 3 acute toxicities included mucositis (n=42) and treatment related pain (n=12). The median follow-up period for surviving patients was 43 months. The 2-year local control rate and overall survival rate were 72.5% and 70.0%, respectively.\nConclusion: Hyperfractionated radiotherapy with concurrent docetaxel is a valuable treatment modality for the management of locally advanced head and neck cancer.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"The 6th S. Takahashi Memorial Symposium & The 6th Japan-US Cancer Therapy International Joint Symposium","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Karasawa, Kumiko"}],"nameIdentifiers":[{"nameIdentifier":"695967","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Matsumoto, Fumihiko"}],"nameIdentifiers":[{"nameIdentifier":"695968","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ito, Shin"}],"nameIdentifiers":[{"nameIdentifier":"695969","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Oba, Shinichi"}],"nameIdentifiers":[{"nameIdentifier":"695970","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Furuya, Tomohisa"}],"nameIdentifiers":[{"nameIdentifier":"695971","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hirowatari, Hisako"}],"nameIdentifiers":[{"nameIdentifier":"695972","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Izawa, Hiromi"}],"nameIdentifiers":[{"nameIdentifier":"695973","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ito, Kana"}],"nameIdentifiers":[{"nameIdentifier":"695974","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sasai, Keisuke"}],"nameIdentifiers":[{"nameIdentifier":"695975","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"唐澤 久美子","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"695976","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Hyperfractionated radiotherapy with concurrent docetaxel in advanced head and neck cancer: a phase II study","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Hyperfractionated radiotherapy with concurrent docetaxel in advanced head and neck cancer: a phase II study"}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2012-07-24"},"publish_date":"2012-07-24","publish_status":"0","recid":"70834","relation_version_is_last":true,"title":["Hyperfractionated radiotherapy with concurrent docetaxel in advanced head and neck cancer: a phase II study"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T19:58:17.730240+00:00"}